EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.54
-0.21 (-5.60%)
▼
5d:
-12.7%
30d:
-22.54%
90d:
+13.83%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EVAX is fairly valued with market pricing in 0.2% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: EVAX is fairly valued with market pricing in 0.2% annual growth. Fine to hold or accumulate slowly on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.54, which is considered oversold relative to its 30-day fair value range of $3.92 to $4.36. The stock's valuation (Forward PE: 88.5) is in line with its historical norms (87.9). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVAX is showing sideways momentum. The price is currently testing key support at $3.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+217.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EVAX is showing sideways momentum. The price is currently testing key support at $3.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+217.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.92 -
$4.36
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 217.8% below Wall St target ($11.25)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
- CAUTION: 5-day price weakness (-12.7%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.92 -
$4.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.50
Resistance Level
$4.25
Current Trend
Sideways
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
88.50
Wall Street Target
$11.25
(+217.8%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-129.6%
Valuation Premium vs History
+0.2% premium
PE vs Historical
88.5 vs 87.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$3.55
(+0%)
2-Year Target
$3.55
(+0%)
3-Year Target
$3.56
(+1%)
3-Yr Target (if PE normalizes)
(PE: 89→88)
PE COMPRESSION
$3.54
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 03, 2026 9:23 PM ET
Data refreshes hourly during market hours. Next update: 10:23 PM
Data refreshes hourly during market hours. Next update: 10:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |